Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tegaserod maleate
Drug ID BADD_D02139
Description Novartis' brand name Zelnorm (tegaserod) had originally received approval from the US FDA in 2002 for the treatment of irritable bowel syndrome with constipation (IBS-C).[L5918,F4229] It was, however, voluntarily withdrawn from widespread use in the US market in 2007 after concerns arose over the possibility that tegaserod could potentially cause dangerous cardiovascular events in patients.[L5918,F4229] Since then, closer evaluations of the original data suggesting such cardiovascular risk have resulted in the limited reintroduction or 're-approval' of tegaserod for treatment of IBS-C specifically in female patients less than 65 years of age and whom are considered to be at a lower risk of a cardiovascular event than the broader population.[L5918,F4229] Zelnorm (tegaserod) by Sloan Pharma subsequently gained re-approval in April of 2019.[L5918] Nevertheless, tegaserod remains un-approved in certain regions.[F4226] Despite the relative complications involved in its history of regulatory approval, ever since its first introduction in 2002 tegaserod remains the only therapy for IBS-C that possesses the unique mechanism of action of acting on serotonin-4 (5-HT(4)) receptors in smooth muscle cells and in the gastrointestinal wall to facilitate actions like esophageal relaxation, peristaltic gut movement, and natural secretions in the gut, among others.[L5918,A11044,A176762,F4229,F4223]
Indications and Usage Tegaserod is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation (IBS-C) [F4223, F4229]. The safety and effectiveness of tegaserod in men with IBS-C have not been established [F4223, F4229].
Marketing Status approved; investigational; withdrawn
ATC Code A06AX06
DrugBank ID DB01079
KEGG ID D02730
MeSH ID C105050
PubChem ID 135413539
TTD Drug ID D00XWD
NDC Product Code 49706-1964
UNII E5XNT3RF5A
Synonyms tegaserod | tegaserod maleate | 5-methoxyindol-3-carboxaldehyde amino(pentylamino)methylenehydrazone hydrogen maleate | Zelnorm | Zelmac | SDZ HTF 919 | HTF 919 | SDZ HTF-919
Chemical Information
Molecular Formula C20H27N5O5
CAS Registry Number 189188-57-6
SMILES CCCCCN=C(N)NN=CC1=CNC2=C1C=C(C=C2)OC.C(=CC(=O)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001---
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Abortion spontaneous18.01.04.001---
Angina pectoris02.02.02.002; 24.04.04.002--
Arthropathy15.01.01.003---
Back pain15.03.04.005--
Bile duct stone09.02.02.003---
Blood creatine phosphokinase increased13.04.01.001--
Breast cancer16.10.01.001; 21.05.01.003---
Chest pain02.02.02.011; 08.01.08.002; 22.12.02.003---
Cholecystectomy25.09.01.001---
Cholecystitis09.03.01.001--
Cholelithiasis09.03.01.002---
Colitis ischaemic07.08.01.004; 24.04.08.012---
Depression19.15.01.001--
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Dysmenorrhoea21.01.01.002--
Dyspepsia07.01.02.001--
Dyspnoea02.11.05.003; 22.02.01.004--
Electrolyte imbalance14.05.01.002---
Eosinophil count increased13.01.06.004---
Fatigue08.01.01.002--
Flatulence07.01.04.002--
Flushing08.01.03.025; 23.06.05.003; 24.03.01.002--
Fungal infection11.03.05.001---
Gastritis07.08.02.001--
Gastrooesophageal reflux disease07.02.02.003--
The 1th Page    1 2 3    Next   Last    Total 3 Pages